Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC0582-0001 · 1 trial · 1 indication
Measured as number of events.
| Arm | Type | Description |
|---|---|---|
| Single Dose 1: NNC0582-0001 10 milligram (mg) | EXPERIMENTAL | Participants will receive a single dose of NNC0582-0001 10 mg or matching placebo injection subcutaneously. |
| Single Dose 2: NNC0582-0001 30 mg | EXPERIMENTAL | Participants will receive a single dose of NNC0582-0001 30 mg or matching placebo injection subcutaneously. |
| Single Dose 3: NNC0582-0001 90 mg | EXPERIMENTAL | Participants will receive a single dose of NNC0582-0001 90 mg or matching placebo injection subcutaneously. |
| Single Dose 4: NNC0582-0001 250 mg | EXPERIMENTAL | Participants will receive a single dose of NNC0582-0001 250 mg or matching placebo injection subcutaneously. |
| Single Dose 5: NNC0582-0001 600 mg | EXPERIMENTAL | Participants will receive a single dose of NNC0582-0001 600 mg or matching placebo injection subcutaneously. |
| Single Dose 6: NNC0582-0001 1000 mg | EXPERIMENTAL | Participants will receive a single dose of NNC0582-0001 1000 mg or matching placebo injection subcutaneously. |
| Name | Type | Description |
|---|---|---|
| NNC0582-0001 | DRUG | Participants will receive single dose of any of the six dose levels of subcutaneous NNC0582-0001 in a sequential manner with the dose increasing between cohorts. |
| Placebo | DRUG | Participants will receive single dose of subcutaneous injection of placebo matched to NNC0582-0001. |
Inclusion Criteria: * Female of non-childbearing potential or male aged 18-55 years (both inclusive) at the time of signing informed consent. * Body Mass Index (BMI) from 20.0 to 30.0 kilogram per square meter (kg/m\^2) (both inclusive) at screening. * Considered to be generally healthy based on th...
NNC0582-0001 is an investigational small molecule being developed by Novo Nordisk A/S. It is currently in Phase 1 clinical development. The drug has been studied in healthy volunteers to assess its safety, tolerability, and how it is transported throughout the body.
NNC0582-0001 is being studied in healthy volunteers as part of early clinical development. The completed Phase 1 trial focused on evaluating the safety, tolerability, and pharmacokinetics of the drug in healthy adults. Its intended therapeutic use has not been established.
NNC0582-0001 is developed by Novo Nordisk A/S, a pharmaceutical company listed on the stock exchange under the ticker NVO. The company is conducting clinical research on this investigational small molecule.
NNC0582-0001 is in Phase 1 clinical development. A Phase 1 study has been completed, which enrolled 56 healthy adult participants. The drug is investigational and has not been approved by regulatory authorities.
NNC0582-0001 has one completed clinical trial registered as NCT05624580. This Phase 1 study was conducted in Austria and enrolled 56 healthy adults. The trial was randomized, double-blind, and controlled, evaluating safety, tolerability, and how the drug is transported in the body.
NNC0582-0001 is the only name provided for this investigational drug. No alternative names have been established in the available clinical trial information.